Yep,,,,read the link,,good find and interesting read for sure. Makes great sense but doesnt offer anything around the main question of diluting real data. It certainly makes for the reasoning around increasing the number count in a trial to help offset the effect of a drop out rate, which is hopefully low. In the case here with BoM,,,the RVX team say their patients wanted to stay on 208 even after their dosing term was reached,,that is a big thumbs up. Anyway,,the read was worth it for sure.

My best suggestion now is ,,to keep your stick on the ice at all times and try your best to stay out of the penelaty box!!!!!wooooohooooo,,,,,I am hoping to see RVX with a strong week here coming!!